Login
Companies $NKTR
$36.29 -$0.15 (0.41%) After hours
NEKTAR THERAPEUTICS logo

NEKTAR THERAPEUTICS

nektar.com

What Do They Do?

Develops experimental immune-modulating medicines for autoimmune diseases and cancer, including treatments designed to restore immune balance or activate the body’s tumor-fighting response.

How Do They Make Money?

Nektar receives royalties tied to partner drug sales, though it has sold rights to receive royalties on several products; it may also receive upfront license payments and payments tied to research, clinical progress, regulatory progress or sales. Its former product sales were paid after shipment.

revenue
SegmentShareRevenue
Product sales
Sold outright
0.0%
FY2022: 22%
Non-cash royalty revenue related to the sales of future royalties
Usage-based

99%
FY2022: 76%
License, collaboration and other revenue
0.5%
FY2022: 2.1%

Who Are Their Customers?

Nektar's revenue comes mainly from pharmaceutical and biotechnology companies through collaboration arrangements. Partners may pay for licenses, research work, clinical or regulatory milestones, and royalties tied to sales of approved drugs.

Customers above 10% of revenue, FY2025
of revenue from three customers (45%, 37%, 14%)
FY2024: 96% from five customers

Do Revenues Turn Into Profits?

No. It lost $164.1M in FY2025.

Operating income, FY2025
−254% of revenue
▼ −33% (Loss) vs FY2024 (−$105.2M, −107%)
Net income, FY2025
−297% of revenue
▼ −38% (Loss) vs FY2024 (−$119M, −121%)
Free cash flow, FY2025
−378% of revenue
▼ −18% (Loss) vs FY2024 (−$177.2M, −180%)

How Are They Changing?

Since the FY2025 annual report
  • Sep 24, 2026 Jury found Lilly breached its agreement and awarded Nektar damages The $90 million award plus interest remains subject to post-trial proceedings and possible appeal.

Shrinking. Revenue fell 46% in 4 years, from $101.9M in FY2021 to $55.2M in FY2025, about 14% a year.

Pipeline focus The older report describes Lilly conducting clinical work on rezpegaldesleukin; the latest report says Nektar has regained full rights and describes its own development of the candidate, alongside preclinical tumor-necrosis-factor receptor candidates.

Research platform The older report describes an advanced polymer-conjugate technology platform and manufacturing PEGylation reagents; the latest report focuses on discovering and developing drug candidates and says the facility was sold.

Revenue over time
Product sales Non-cash royalty revenue related to the sales of future royalties License, collaboration and other revenue
$200M$100M$0

Who Do They Compete With?

Competes with Regeneron, Leo Pharma, Eli Lilly and, Galderma, Symbiotix, Apogee Therapeutics, Janssen Pharmaceuticals, AstraZeneca, Tizona Therapeutics, Sangamo Therapeutics, Quell Therapeutics, Sonoma Biotherapeutics, GentiBio, Kyvema Therapeutics, Tract Therapeutics, Sanofi SA, ImmunityBio, Nkarta, NKMax America, and Roche/Genentech

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support